Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.
FAIL · Does not pass the screen
26.36 USD
At the last full screen 2026-08-26
Screened 2026-08-26 · the tape above runs as of 10:31 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markdown label.
Dyne Therapeutics, Inc. holds its Markdown at $26.36. Consolidating, no directional conviction, held for 16 days.
As held on the ledger · 2026-08-26
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 16 days
Price at the screen
$26.36
Valuation
N/A trailing · -7.89 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.08
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
14.25%
Below 33%
Interest-bearing debt is just 14.3% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
18.30%
Below 33%
Cash held in interest-bearing accounts and securities is 18.3% of assets, under the one-third limit.
Pass
Receivables
75.27%
Below 49%
Money owed to the company is 75.3% of assets, above the 49% limit.
Fail
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-08-26 screen. The gold marker is the market price at the same screen. A 51.7% margin of safety to the base estimate.
Third-party analyst targets: 15 covering, consensus Strong Buy. The average target sits +52% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-08-26 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Clinical Biotech Stumbles on Missing Ethical Data
Dyne is trying to build drugs that could one day treat rare muscle wasting diseases, the kind that leave families waiting years for any real option. Yet the company is still clinical stage, burning cash with no approved products and zero profit margin to show for it. That leaves the investment case resting on hope and analyst targets rather than any track record of turning science into cash.
We pass because the ethical screen returns insufficient data and the opportunity rating sits at none. Forward earnings sit at a negative 8.1 times while return on equity runs at minus 59 percent, the typical profile for a firm that has never made money. Without the basic financial ratios needed for a proper screen, there is no foundation to weigh the business against our standards.
High failure rates in neuromuscular trials add another layer of risk, and currency or sector swings could hit sentiment fast. The market may price in success at forty dollars, but without earnings or ethical clarity that number remains just a guess. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
DYN trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 11.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 8% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 19%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (16 analysts) rates it strong buy, with a mean price target of $38.
2026-07-27Markup$23.74+30.5%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 30.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 8% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 19%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (16 analysts) rates it strong buy, with a mean price target of $38.
2026-07-18Markup$18.19+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 8% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 19%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (16 analysts) rates it strong buy, with a mean price target of $38.
2026-07-03Markup$18.19+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markup$18.19Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
